ELFN1 and neoplasm: To validate the tumor-promoting function of SMIMP with a complementary approach to the CRISPR–Cas9 method, we performed small interfering RNA (siRNA)-mediated knockdown of ELFN1-AS1 by designing two siRNA species targeting the regions outside its CDS.